Cerebral microvascular impairments occurring in AD may reduce A clearance
Expected outcomes based on trial data: Average weight loss of 24.2% at 48 weeks (phase 2) Average weight loss of 28.7% at 68 weeks (phase 3, TRIUMPH-4) 100% of participants achieved 5% or greater weight loss 93% achieved 10% or greater 83% achieved 15% or greater Moderate weight loss protocol (8mg target) For researchers who want significant weight loss but have a lower tolerance for side effects, stopping the escalation at 8mg is a validated approach
We do know that GLP-1s have powerful anti-inflammatory effects, but we dont yet fully understand: Long-term impact on Lipedema fat Effect on fibrosis Impact on lymphatic health Interaction with Lipedema-specific metabolic patterns For now, the approach must be personalised, cautious, and monitored
BelaunzaranZamudio at the National Institute of Allergy and Infectious Diseases
Explore the efficacy of Tirzepatide in reducing body weight, enhancing metabolic health, and managing weight-related medical conditions at Set Point Medical Weight Loss Clinic
This usually happens 4-6 weeks after pregnancy loss
